Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

o papers were published in Clinical Cancer Research covering

preclinical work with reovirus in combination with radiation, and

reovirus administration following cyclophosphamide.

- In April, two presentations were made at the American Association for

Cancer Research (AACR) covering work using the reovirus in

combination with radiation for pediatric sarcomas, and reovirus as a

purging agent for autologous stem cell transplants.

- In April, a paper covering preclinical work demonstrating that

reovirus can kill melanoma cell lines and freshly resected tumour was

published in Gene Therapy.

Intellectual Property

- Two Canadian patents and one U.S. patent were secured in the quarter.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

This discussion and analysis should be read in conjunction with the unaudited consolidated financial statements of Oncolytics Biotech Inc. as at and for the three months ended March 31, 2008 and 2007, and should also be read in conjunction with the audited financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") contained in our annual report for the year ended December 31, 2007. The financial statements have been prepared in accordance with Canadian generally accepted accounting principles ("GAAP").

FORWARD-LOOKING STATEMENTS

The following discussion contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including our belief as to the potential of REOLYSIN(R) as a cancer therapeutic and our expectations as to the success of our research and development and manufacturing programs in 2008 and beyond, future financial position, business strategy and plans for future operations, and statements t
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... University of Leicester has furthered our understanding of ... create new materials using nanosized ,building blocks,. , ... prestigious academic journal Physical Review Letters , ... rich detail the structure and internal atomic motion ... and a single helium atom. , The technique ...
(Date:7/25/2014)... WABC Radio show out of New York ... Young will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, ... in pets. Dr. Harman first visited the show in ... for pets suffering from osteoarthritis and other degenerative diseases, as ... forward. , Young has invited Dr. Harman back to dial ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/25/2014)... Sinovac Biotech Ltd. (Nasdaq: SVA ), ... , today announced that it will release its unaudited ... after market close on Thursday, August 14, 2014 EDT. The ... opening on Friday, August 15, 2014, at 8:00 a.m. EDT ... to review the Company,s financial results and provide an update ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... , EAST BRUNSWICK, N.J., Sept. 8 Savient ... abstracts relating to KRYSTEXXA(TM) (pegloticase) development and treatment failure gout will ... in Philadelphia from October 16-21, 2009. The posters will be ... and include: , , , ...
... , CAMBRIDGE, Massachusetts, September 8 ... the global specialty biopharmaceutical company, is,committed to doing everything ... imiglucerase supply shortage. Shire is pleased to be,able to ... previously,anticipated commercial launch world wide. , ...
... , SAN DIEGO, Sept. 8 Biomatrica, Inc., the ... key appointments that will expand the breadth of leadership and commercial ... continued rapid growth in the development and commercialization of products for ... , Martin Latterich, Ph.D., has joined the company ...
Cached Biology Technology:Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 3Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 4Update on velaglucerase alfa 2Update on velaglucerase alfa 3Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 2Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 3Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 4Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 5
(Date:7/25/2014)... the Terra satellite show the different areas that have been ... The burn scars show up as reddish-brown splotches of ... across the remote parts of Eastern Russia in the Sakha ... instrument, it is still possible to see the smoke ... noted below show the devastating number of fires that have ...
(Date:7/25/2014)... of biomedical engineering at the University of Houston, ... and artificial organ development., "Introduction to Tissue Engineering: ... entering into the field of artificial organ development. ... engineering at UH, served as a series editor ... are other published books on the subject of ...
(Date:7/25/2014)... (DTT), which is derived from diffusion tensor imaging ... tracts, such as the corticospinal tract, the rubrospinal ... corticospinal tract is known to be a major ... brain. Several studies have reported on injury of ... some studies have demonstrated recovery of a corticospinal ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2
... pressure were recently identified in a comprehensive international ... study, in which Uppsala University researchers participated, are ... Nature Genetics . High blood pressure ... Previous studies have shown that it is extremely ...
... May 8 Military and civilian personnel from the ... local homeland security, law enforcement and other first-responder personnel ... been encouraged to register and attend the 2009 Force ... held at Stafford Regional Airport and Marine Corps Base, ...
... and south sides of a house may decrease summertime ... a recent study* of California homes by researchers from ... the U.S. Department of Agriculture (USDA). The first ... the effects of shade on 460 single-family homes in ...
Cached Biology News:Comprehensive genetic study paves way for new blood-pressure medicines 2Demonstration Features Commercial Technology for Combating Terrorism 2New study: Home energy savings are made in the shade 2
Moue Serum 8-12 Weeks Old...
... is collected off the clot fasted non-Swiss Albino mice ... Available Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) ... CPD N-09: K3EDTA N-11: ...
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
Biology Products: